What is a Cosmetic Product Safety Report (CPSR)?
A cosmetic product needs to be safe for human health when used under normal and reasonably foreseeable conditions of use. All cosmetic products placed on the EU market must be subject to a safety assessment conducted by a qualified person. A Cosmetic Product Safety Report (CPSR) shall be done and included in the Product Information File (PIF).
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate

EU LEGAL FRAMEWORK ON COSMETIC PRODUCTS

The Regulation (EC) No 1223/2009 establishes the rules that all cosmetic products made available on the European Union (EU) market must comply with, in order to ensure the functioning of the internal market and a high level of protection of human health.

Only cosmetic products for which a legal or natural person is designated as a “Responsible Person” (RP) can be placed on the EU market. The RP is fully responsible for safety and legal compliance. (see previous post)

According to Article 3 of this Regulation, “a cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use“. In order to demonstrate that a cosmetic product complies with Article 3, the RP must guarantee that the product has undergone a safety assessment and that a Cosmetic Product Safety Report (CPSR) is set up.

The CPSR must be carried out by a qualified safety assessor, with a university diploma (or other evidence of formal qualification) in pharmacy, toxicology, medicine or similar (recognized as equivalent by a Member State).

COSMETIC PRODUCT SAFETY REPORT (CPSR)

The CPSR consists of two parts (Part A and Part B) that should contain, as minimum, the following information:

  • PART A – Cosmetic product safety information
    • Quantitative and qualitative composition of the cosmetic product
    • Physical/chemical characteristics and stability of the cosmetic product
    • Microbiological quality
    • Impurities, traces, information about the packaging material
    • Normal and reasonably foreseeable use
    • Exposure to the cosmetic product
    • Exposure to the substances
    • Toxicological profile of the substances
    • Undesirable effects and serious undesirable effects
    • Information on the cosmetic product

  • PART B – Cosmetic product safety assessment
    • Assessment conclusion
    • Labelled warnings and instructions of use
    • Reasoning
    • Assessor’s credentials and approval of part B

The CPSR must be kept up to date, taking into acount relevant information generated after the product is placed on the market (e.g., amendments to Regulation).

The Cosmetic Product Safety Report is part of the Product Information File (PIF), which should be kept for a period of 10 years, counting on the date on which the last batch of the product was placed on the market.

In sum, the CPSR is a mandatory document for all cosmetic products in the EU, as it demonstrates the safety and efficacy of a cosmetic product.

Critical Catalyst has a team of qualified EU safety assessors with vast experience in conducting CPSRs. For more information, please feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.

further
reading

news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »